NilotinibDEININGER, Michael W.Clinical cancer research. 2008, Vol 14, Num 13, pp 4027-4031, issn 1078-0432, 5 p.Article

Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemiaDEININGER, Michael W. N.Journal of cancer research and clinical oncology. 2004, Vol 130, Num 2, pp 59-72, issn 0171-5216, 14 p.Article

Resistance to Imatinib: Mutations and BeyondLA ROSEE, Paul; DEININGER, Michael W.Seminars in hematology. 2010, Vol 47, Num 4, pp 335-343, issn 0037-1963, 9 p.Article

Selection of Therapy: Rational Decisions Based on Molecular EventsKHORASHAD, Jamshid S; DEININGER, Michael W. N.Hematology/oncology clinics of North America. 2011, Vol 25, Num 5, issn 0889-8588, 1009-1023, vi [16 p.]Article

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemiaO'HARE, Thomas; EIDE, Christopher A; DEININGER, Michael W. N et al.Blood. 2007, Vol 110, Num 7, pp 2242-2249, issn 0006-4971, 8 p.Article

The molecular biology of chronic myeloid leukemiaDEININGER, Michael W. N; GOLDMAN, John M; MELO, Junia V et al.Blood. 2000, Vol 96, Num 10, pp 3343-3356, issn 0006-4971Article

Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled TrialMESA, Ruben A; GOTLIB, Jason; HARVEY, Jimmie H et al.Journal of clinical oncology. 2013, Vol 31, Num 10, pp 1285-1292, issn 0732-183X, 8 p.Article

Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CMLAGARWAL, Anupriya; FLEISCHMAN, Angela G; PETERSEN, Curtis L et al.Blood. 2012, Vol 120, Num 13, pp 2658-2668, issn 0006-4971, 11 p.Article

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CMLO'HARE, Thomas; POLLOCK, Roy; YIHAN WANG et al.Blood. 2004, Vol 104, Num 8, pp 2532-2539, issn 0006-4971, 8 p.Article

Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignanciesSONNICHSEN, Daryl; DORER, David J; LITWIN, Jeffrey et al.Cancer chemotherapy and pharmacology. 2013, Vol 71, Num 6, pp 1599-1607, issn 0344-5704, 9 p.Article

TNFα facilitates clonal expansion of JAK2^V617F positive cells in myeloproliferative neoplasmsFLEISCHMAN, Angela G; AICHBERGER, Karl J; LORIAUX, Marc M et al.Blood. 2011, Vol 118, Num 24, pp 6392-6398, issn 0006-4971, 7 p.Article

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinibSHERBENOU, Daniel W; HANTSCHEL, Oliver; SUPERTI-FURGA, Giulio et al.Blood. 2010, Vol 116, Num 17, pp 3278-3285, issn 0006-4971, 8 p.Article

In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell linesLA ROSEE, Paul; JOHNSON, Kara; CORBIN, Amie S et al.Blood. 2004, Vol 103, Num 1, pp 208-215, issn 0006-4971, 8 p.Article

Threshold Levels of ABL Tyrosine Kinase Inhibitors Retained in Chronic Myeloid Leukemia Cells Determine Their Commitment to ApoptosisO'HARE, Thomas; EIDE, Christopher A; RIDDLE, Steven M et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 11, pp 3356-3370, issn 0008-5472, 15 p.Article

Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survivalKYUNG HEE CHANG; SANCHEZ-AGUILERA, Abel; AGIRRE, Xabier et al.Blood. 2012, Vol 120, Num 4, pp 800-811, issn 0006-4971, 12 p.Article

The BCR-ABL^35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemiaO'HARE, Thomas; ZABRISKIE, Matthew S; TOPLIN, Julie et al.Blood. 2011, Vol 118, Num 19, pp 5250-5254, issn 0006-4971, 5 p.Article

BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CMLPRESS, Richard D; LOVE, Zac; TRONNES, Ashlie A et al.Blood. 2006, Vol 107, Num 11, pp 4250-4256, issn 0006-4971, 7 p.Article

Cytogenetic studies in patients on imatinibDEININGER, Michael W. N.Seminars in hematology. 2003, Vol 40, Num 2, pp 50-55, issn 0037-1963, 6 p., SUP2Conference Paper

MET Receptor Sequence Variants R970C and T992I Lack Transforming CapacityTYNER, Jeffrey W; FLETCHER, Luke B; LORIAUX, Marc M et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 15, pp 6233-6237, issn 0008-5472, 5 p.Article

Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative diseaseAGARWAL, Anupriya; BUMM, Thomas G. P; DEININGER, Michael W et al.Blood. 2008, Vol 112, Num 5, pp 1960-1970, issn 0006-4971, 11 p.Article

RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518WALTERS, Denise K; STOFFREGEN, Eric P; HEINRICH, Michael C et al.Blood. 2005, Vol 105, Num 7, pp 2952-2954, issn 0006-4971, 3 p.Article

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinibCORBIN, Amie S; LA ROSEE, Paul; STOFFREGEN, Eric P et al.Blood. 2003, Vol 101, Num 11, pp 4611-4614, issn 0006-4971, 4 p.Article

A phase 2 study of imatinib in patients with relapsed or refractory philadelphia chromosome-positive acute lymphoid leukemiasOTTMANN, Oliver G; DRUKER, Brian J; BACCARANI, Michele et al.Blood. 2002, Vol 100, Num 6, pp 1965-1971, issn 0006-4971, 7 p.Article

Biology of chronic myelogenous leukemia-signaling pathways of initiation and transformationMELO, Junia V; DEININGER, Michael W. N.Hematology/oncology clinics of North America. 2004, Vol 18, Num 3, pp vii-viii, issn 0889-8588, 26 p.Article

Practical management of patients with chronic myeloid leukemia receiving imatinibDEININGER, Michael W. N; O'BRIEN, Stephen G; FORD, John M et al.Journal of clinical oncology. 2003, Vol 21, Num 8, pp 1637-1647, issn 0732-183X, 11 p.Article